FIGURE 10.

SOCS2-AS1-overexpressing cells are more resistant to docetaxel treatment and apoptosis. A, MTS assay of LNCaP stable cells treated with 2 nm docetaxel or DMSO for the indicated times. B, TUNEL assay in LNCaP stable cells treated with 2 nm docetaxel for 48 h. Shown are DAPI (upper panels)- and Alexa Fluor 488 (lower panels)-stained docetaxel-treated stable cells. C, quantification of apoptotic cells of TUNEL assay. Data represent the average of three different views (n = 3). Vec, vector. Values represent mean ± S.D. **, p < 0.01. D, docetaxel-induced apoptosis is inhibited in SOCS2-AS1 stably expressing cells. PARP cleavage was analyzed by Western blotting in LNCaP cells stably expressing SOCS2-AS1 or SOCS2 and control cells treated with 1 nm docetaxel for 48 h. PARP and cleaved PARP antibodies were used. PARP proenzyme (116 kDa) and the cleaved subunit, c-PARP (89 kDa), are indicated on the left by arrows. β-Actin was used as a loading control. IB, immunoblot.